Anika Therapeutics, Inc.
ANIK- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0000898437
In the last 90 days, Anika Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 133 institutions reported holding it in 13F filings for Q2 2026, worth $179.0M in total; no superinvestor holds it.
Holders of 5% or more of ANIK
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Anika Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Caligan Partners LP | 13D/A | 9.95%1.44M shares | 0.00 ppfrom 9.95% | Aug 17, 20236 filings | Jan 27, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 6.80%963.1K shares | −3.80 ppfrom 10.60% | Oct 23, 20244 filings | Apr 17, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
51 Schedule 13D and 13G filings on Anika Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jan 25, 20214:56 PM ET | BlackRock Inc. | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
1 notice from officers, directors and other affiliates planning to sell Anika Therapeutics, Inc. shares, newest first.
| Filed (ET) | Seller | Shares to sell | Market value | Planned sale | Broker | Filing |
|---|---|---|---|---|---|---|
| Aug 7, 20265:28 PM ET | Jellison William RFormer director | 16.9K | $355.3K | Aug 7, 2026 | Fidelity Brokerage Services LLC | SEC |